# Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

> **NCT07102511** · PHASE3 · NOT_YET_RECRUITING · sponsor: **LIB Therapeutics LLC** · enrollment: 150 (estimated)

## Conditions studied

- Familial Hypercholesterolemia - Heterozygous

## Interventions

- **BIOLOGICAL:** lerodalcibep 300 mg Monthly SC

## Key facts

- **NCT ID:** NCT07102511
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102511, "Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07102511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*